Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease

Haematologica

Volumn 87, Issue 3, 2002, Pages 299-305

  Schetelig, Johannes ^a   Kröger, Nicolaus ^a   Held, Thomas K ^a   Thiede, Christian ^a   Krusch, Andreas ^a   Zabelina, Tatjana ^a   Dubiel, Marc ^a   Rick, Oliver ^a   Bornhäuser, Martin ^a   Ehninger, Gerhard ^a   Zander, Axel R ^a   Siegert, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Allogeneic stem cell transplantation; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGRAFT; ARTICLE; CELL COUNT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONDITIONING; FEMALE; FEVER; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MALE; MORTALITY; PROPHYLAXIS; SIDE EFFECT; SOLID TUMOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT CONTRAINDICATION;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RISK; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036192691     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
2. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
3. Venoocclusive disease of the liver following bone marrow transplantation
4. 1994 Consensus Conference on Acute GVHD Grading
5. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
6. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
7. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
8. Non-myeloablative allogeneic transplantation with edjuvant dose escalated donor lymphocyte infusions for multiple myeloma
9. Dose-reduced conditioning for allografting in 45 patients with CML: A retrospective analysis
10. Well-tolereted nonmyeloablative fludarabine-based protocols for the treatment of malignant and non-malignant disorders with allogeneic bone marrow or blood stem cell transplantation
11. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation
12. Non-myeloebletive stem cell transplants
13. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy
14. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
15. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
16. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation
17. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft
18. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age: A single institution's experience
19. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
20. Bone marrow transplantation in patients aged 45 years and older
21. Second allogeneic transplantation after failure of first autologous transplantation
22. Older patient age remains a risk factor for transplant related mortality following nonmyeloablative allogeneic stem cell transplantation